Iovance obtained approval for Amtagvi last year, which has given its top line a big boost. This year, the company anticipates it can generate up to $300 million in sales. Though it’s unprofitable, …
Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around?
view original post